The cytokines in tumor microenvironment: from cancer initiation-elongation-progression to metastatic outgrowth
- PMID: 38442808
- DOI: 10.1016/j.critrevonc.2024.104311
The cytokines in tumor microenvironment: from cancer initiation-elongation-progression to metastatic outgrowth
Abstract
It is a well-known fact that cancer can be augmented by infections and inflammation. In fact, chronic inflammation establishes a tumor-supporting-microenvironment (TME), which contributes to neoplastic progression. Presently, extensive research is going on to establish the interrelationship between infection, inflammation, immune response, and cancer. Cytokines are the most essential components in this linkage, which are secreted by immune cells and stromal cells of TME. Cytokines have potential involvement in tumor initiation, elongation, progression, metastatic outgrowth, angiogenesis, and development of therapeutic resistance. They are also linked with increased cancer symptoms along with reduced quality of life in advanced cancer patients. The cancer patients experience multiple symptoms including pain, asthenia, fatigue, anorexia, cachexia, and neurodegenerative disorders etc. Anti-cancer therapeutics can be developed by targeting cytokines along with TME to reduce the immunocompromised state and also modulate the TME. This review article depicts the composition and function of different inflammatory cells within the TME, more precisely the role of cytokines in cancer initiation, elongation, and progression as well as the clinical effects in advanced cancer patients. It also provides an overview of different natural compounds, nanoparticles, and chemotherapeutic agents that can target cytokines along with TME, which finally pave the way for cytokines-targeted anti-cancer therapeutics.
Keywords: Advanced cancer; Cytokines; Infection; Inflammation; Therapeutic strategies; Tumor growth and progression; Tumor microenvironment (TME).
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors have no competing financial and/or non-financial interests to declare that are relevant to the content of this article.
Similar articles
-
Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication.Mol Cancer. 2024 Nov 30;23(1):268. doi: 10.1186/s12943-024-02183-9. Mol Cancer. 2024. PMID: 39614288 Free PMC article. Review.
-
The Interplay Between Inflammation and Stromal Components in Pancreatic Cancer.Front Immunol. 2022 Apr 14;13:850093. doi: 10.3389/fimmu.2022.850093. eCollection 2022. Front Immunol. 2022. PMID: 35493517 Free PMC article. Review.
-
The Role of Tumor Microenvironment Cells in Colorectal Cancer (CRC) Cachexia.Int J Mol Sci. 2021 Feb 4;22(4):1565. doi: 10.3390/ijms22041565. Int J Mol Sci. 2021. PMID: 33557173 Free PMC article. Review.
-
Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance.Cancer Metastasis Rev. 2023 Sep;42(3):959-1020. doi: 10.1007/s10555-023-10119-w. Epub 2023 Jul 28. Cancer Metastasis Rev. 2023. PMID: 37505336 Review.
-
Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond.Semin Oncol. 2014 Apr;41(2):235-51. doi: 10.1053/j.seminoncol.2014.02.007. Epub 2014 Feb 28. Semin Oncol. 2014. PMID: 24787295 Review.
Cited by
-
Pro-Inflammatory Cytokines Transactivate Glycosylated Cytokine Receptors on Cancer Cells to Induce Epithelial-Mesenchymal Transition to the Metastatic Phenotype.Cancers (Basel). 2025 Apr 5;17(7):1234. doi: 10.3390/cancers17071234. Cancers (Basel). 2025. PMID: 40227834 Free PMC article.
-
Cancer-on-a-chip for precision cancer medicine.Lab Chip. 2025 Jul 8;25(14):3314-3347. doi: 10.1039/d4lc01043d. Lab Chip. 2025. PMID: 40376718 Free PMC article. Review.
-
LncRNAs regulates cell death in osteosarcoma.Sci Rep. 2025 Jul 2;15(1):22592. doi: 10.1038/s41598-025-04440-3. Sci Rep. 2025. PMID: 40595878 Free PMC article.
-
Integration of single-cell RNA and bulk RNA sequencing revealed malignant ductal cell heterogeneity and prognosis signatures in pancreatic cancer.Front Immunol. 2025 Jul 1;16:1579184. doi: 10.3389/fimmu.2025.1579184. eCollection 2025. Front Immunol. 2025. PMID: 40666516 Free PMC article.
-
Phospholipid-Drug Conjugates in Cancer Therapy: Emerging Paradigms and Future Directions.AAPS PharmSciTech. 2025 Jul 14;26(6):190. doi: 10.1208/s12249-025-03175-8. AAPS PharmSciTech. 2025. PMID: 40659903 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical